Chiasma Partners With Roche in Deal Worth Up to $600 Million

The Israeli start-up and Swiss pharmaceutical giant will cooperate in the development of Chiasma's original drug and collaborate on future products.

comments Print
The Israeli pharmaceutical start-up company Chiasma chalked up a significant achievement when it signed a commercialization agreement with Swiss pharmaceutical giant Roche for up to $530 million.